NR3C1 and breast cancer: Notably, pharmaceutical agents modulating the activity of ER, AR, RAR, and GR are presently employed in the treatment regimens for breast cancer, prostate cancer, APL, and acute lymphoblastic leukemia, respectively [18, 126].